Advertisement

Search Results

Advertisement



Your search for The ,The matches 34676 pages

Showing 33551 - 33600


colorectal cancer
issues in oncology

FDA Panel Endorses Stool-Based DNA Colon Cancer Test

The U.S. Food and Drug Administration’s (FDA) committee of genetic experts has determined that Cologuard, a stool-based DNA, noninvasive screening test for colorectal cancer, has demonstrated safety, effectiveness, and a favorable risk-benefit profile. The FDA is now considering the...

lung cancer
issues in oncology

Ceritinib Highly Active in Patients With ALK-Rearranged Advanced NSCLC, Including Those With Prior Crizotinib Treatment

Non–small cell lung cancer (NSCLC) harboring ALK rearrangement is sensitive to the ALK inhibitor crizotinib (Xalkori), but resistance ultimately occurs. In a phase I study reported in The New England Journal of Medicine, Shaw et al found that the more-potent ALK inhibitor ceritinib was...

cns cancers

Metastatic Neuroblastoma Confined to Distant Lymph Nodes Associated With Better Survival Compared With Other Stage IV Disease

The pattern of metastatic spread is not incorporated into current risk-stratification systems for neuroblastoma. In a retrospective study reported in the Journal of Clinical Oncology, Morgenstern et al found that patients with neuroblastoma with metastatic disease limited to distant lymph nodes...

leukemia

Long-Term Benefit With Dasatinib After Imatinib Failure in Chronic-Phase CML

Patients with chronic myeloid leukemia (CML) in the chronic phase who are resistant or intolerant to imatinib (Gleevec) can experience long-term benefit with dasatinib (Sprycel), according to results of a randomized phase III study. The CA180-034 study also found that early molecular and...

breast cancer
issues in oncology

Gene Implicated in Progression and Relapse of Triple-Negative Breast Cancer

Scientists from Weill Cornell Medical College, New York, and Houston Methodist, Houston, have found that a gene previously unassociated with breast cancer plays a pivotal role in the growth and progression of the triple-negative form of the disease. The research by Chen et al, published in Nature,...

leukemia
myelodysplastic syndromes

Prolonged Administration of Azacitidine Improves Response in Myelodysplasia, Less So in Combination With Entinostat

In the phase II US Leukemia Intergroup Trial E1905 reported in the Journal of Clinical Oncology, Prebet et al found that prolonged administration of lower-dose azacitidine produced a high response rate in patients with myelodysplastic syndrome or acute myeloid leukemia (AML) with myelodysplastic...

cns cancers

Pemetrexed and Gemcitabine Show Promise Against Aggressive Childhood Brain Tumor

The quest to improve survival of children with a high-risk brain tumor has led investigators at St. Jude Children's Research Hospital to two drugs already used to treat adults with breast, pancreatic, lung, and other cancers. The study by Morfouace at al was published today in Cancer Cell....

solid tumors
issues in oncology

Tumor Size, Location, and Mitotic Rate, but Not Genotype, Associated With Recurrence-Free Survival in Trial of Adjuvant Imatinib vs Placebo in GIST

The ACOSOG Z9001 (Alliance) study showed that 1 year of adjuvant imatinib (Gleevec) prolonged recurrence-free survival after resection of primary gastrointestinal stromal tumors (GIST). As reported by Corless et al in the Journal of Clinical Oncology, a study evaluating correlation of pathologic...

breast cancer

Continued Event-Free Survival Benefit of Neoadjuvant/Adjuvant Trastuzumab in HER2-Positive Locally Advanced Breast Cancer

As reported by Gianni et al in The Lancet Oncology, long-term follow-up of women with HER2-positive locally advanced breast cancer receiving neoadjuvant chemotherapy alone vs with neoadjuvant and adjuvant trastuzumab (Herceptin) in the phase III NOAH trial has shown continued event-free survival...

issues in oncology

Electronic Cigarette Usage Associated With Use of Conventional Cigarettes Among Adolescents

“Use of e-cigarettes does not discourage, and may encourage, conventional cigarette use among US adolescents.” This was the conclusion of a cross-sectional analysis of survey data from a representative sample of middle and high school students who completed the National Youth Tobacco...

lung cancer

Immunotherapy Data Herald New Era of Lung Cancer Treatment

A new era of lung cancer therapy is dawning, using drugs that can prevent tumor cells from evading the immune system, experts reported at the 4th European Lung Cancer Congress. For decades, scientists and doctors thought immunotherapy was of marginal benefit in lung cancer, said ESMO spokesperson...

lymphoma

Omitting Radiotherapy in Early PET-Negative Stage I/II Hodgkin Lymphoma Is Associated With Increased Risk of Early Relapse

The EORTC/LYSA/FIL Intergroup H10 trial assessed whether omitting involved-node radiotherapy would affect progression-free survival in patients with negative early positron-emission tomography (PET) scans after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) compared with...

lung cancer

Erlotinib and Gefitinib Offer Similar Benefit in EGFR-Mutated Non–Small Cell Lung Cancer

A retrospective study has shown that two targeted therapy drugs—erlotinib (Tarceva) and gefitinib (Iressa)—achieved similar outcomes among people with metastatic or recurrent non–small cell lung cancer (NSCLC) harboring an EGFR mutation. These EGFR tyrosine kinase inhibitors have...

lung cancer

Phase III Study: Crizotinib Prolongs Progression-Free Survival in Previously Untreated ALK-Positive Advanced NSCLC

In the phase III PROFILE 1014 study, the anaplastic lymphoma kinase (ALK) inhibitor crizotinib (Xalkori) was found to significantly prolong progression-free survival in previously untreated patients with ALK-positive advanced nonsquamous non–small cell lung cancer (NSCLC) compared with...

gynecologic cancers

Locoregional Progression of Cervical Cancer Follows Reverse Ontogenetic Sequence

In a study reported in The Lancet Oncology, Höckel et al demonstrated that locoregional progression of cervical cancer follows the reverse sequence of establishment of adult tissues in ontogeny. Ontogenetic staging was a better predictor of survival than pathologic staging. Previous work by...

leukemia

Phase II Study Suggests Benefit of Adding Rituximab to Chlorambucil in First-Line Treatment for Chronic Lymphocytic Leukemia

In a UK phase II study reported in the Journal of Clinical Oncology, Hillmen et al assessed the safety and activity of adding rituximab (Rituxan) to chlorambucil (Leukeran) in first-line treatment of chronic lymphocytic leukemia (CLL). Such a regimen may be an alternative to fludarabine-based...

gynecologic cancers
issues in oncology

PARP Inhibitor Veliparib Might Benefit Women With Resistant Gynecologic Cancers and BRCA Mutation

Preliminary research suggests that a targeted oral agent may improve outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies. According to a phase II study presented at the Society of Gynecologic...

breast cancer

Lymphedema Lingers Long After Sentinel Lymph Node Dissection for Early Breast Cancer

Patients with early-stage breast cancer who underwent sentinel lymph node dissection experienced lymphedema more frequently than clinically suspected and with increasing incidence over time, according to a presentation at the 2014 Society of Surgical Oncology (SSO) Cancer Symposium in Phoenix...

head and neck cancer

Long-Term Use of Valproic Acid May Reduce the Risk of Head and Neck Cancer

The antiseizure medication and mood stabilizer valproic acid was associated with a significant reduction in head and neck cancer risk, according to a study recently published in Cancer. The large retrospective cohort study by Kang et al was conducted to evaluate the effects of the drug, a histone...

sarcoma

Long-Term Follow-up Shows Surgery Plus Radiation Offers Mixed Results in Soft-Tissue Sarcoma

Adjuvant radiation following surgery for soft-tissue sarcoma of the extremities did not lead to a survival benefit and seemed to be associated with some degree of long-term limb complications, according to a presentation at the 2014 Society of Surgical Oncology (SSO) Cancer Symposium in Phoenix...

colorectal cancer
issues in oncology

Stool Multitarget DNA Test More Sensitive, But Less Specific Than Fecal Immunochemical Test for Colorectal Cancer Screening in Persons at Average Risk

In a study reported in The New England Journal of Medicine, Imperiale et al found that a noninvasive, multitarget stool DNA test—including assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, β-actin, and hemoglobin—was significantly more sensitive but significantly less ...

issues in oncology
issues in oncology

Study Finds Oncologists Have Mixed Attitudes on the Use of Genomic Testing

While many cancer researchers believe that predictive somatic genomic testing holds the potential to usher in the era of precision medicine for patients with cancer, research by Gray et al suggests that not all physicians are eager to embrace the technology. The variation in attitudes was in part...

gynecologic cancers

Risk Factors for Gastrointestinal Adverse Events Studied in Setting of First-Line Bevacizumab/Chemotherapy for Ovarian Cancer

As reported in the Journal of Clinical Oncology, Burger et al assessed risk factors for gastrointestinal adverse events in women with advanced ovarian cancer receiving first-line bevacizumab (Avastin)/chemotherapy with or without bevacizumab maintenance or chemotherapy alone in the phase III...

gynecologic cancers
gynecologic cancers

Women With Gynecologic Cancers May Live Longer When Treated at High-Volume Medical Centers

Women with ovarian and other gynecologic cancers live significantly longer when they receive care at hospitals that treat a large number of patients with these conditions, according to research on more than 850,000 women. The findings, based on information from the nation’s largest cancer...

gynecologic cancers
issues in oncology

Women With BRCA1 Mutations May Still Be at Risk for Rare Types of Uterine Cancer After Preventive Salpingo-Oophrectomy

Women with BRCA1 mutations may have an increased risk for developing rare types of aggressive uterine cancer despite having their ovaries and fallopian tubes removed, suggest preliminary findings presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer held ...

gynecologic cancers

Bariatric Surgery May Lower Risk of Uterine Cancer

Women who had bariatric surgery to lose weight had a 70% lower risk of uterine cancer and an even lower risk if they kept the weight off, according to findings presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, held in Tampa, Florida, from March 22 to 25. ...

breast cancer
issues in oncology

Audit of NHS Breast Cancer Screening Programme Reveals Significant Variations Between Hospitals in Treatment Outcomes for DCIS

Analysis of data from the UK NHS Breast Screening Programme has shown significant variations in the outcomes of treatment for women with ductal carcinoma in situ (DCIS) between UK hospitals. Dr. Jeremy Thomas, a consultant pathologist at the Western General Hospital, Edinburgh, told the 9th...

breast cancer

ASCO Issues Updated Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer

A review by ASCO’s Update Committee of new data from randomized clinical trials has led to a change in recommendations for the use of sentinel lymph node biopsy in patients with early-stage breast cancer. The updated guideline will enable more women with early-stage breast cancer to avoid the ...

breast cancer
issues in oncology

Harms Outweigh Benefits for Women Aged 70 and Over in National Breast Cancer Screening Programs

Extending national breast cancer screening programs to women over the age of 70 does not result in a decrease in the number of cancers detected at advanced stages, according to new research from The Netherlands. Instead, researchers told attendees at the 9th European Breast Cancer Conference that...

lung cancer

Investigational Cancer Vaccine Shows Renewed Potential in Non–Small Cell Lung Cancer

Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic agent cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. The study also found that radiation treatments did not...

breast cancer

Obesity and Diabetes Have Adverse Effects on Outcomes Across Breast Tumor Types, Should Be Taken Into Account When Planning Treatment

Both obesity and diabetes have adverse effects on outcomes in breast cancer patients who receive neoadjuvant chemotherapy, according to research presented at the 9th European Breast Cancer Conference. Although a high body mass index (BMI) is known to have a negative impact on cancer development and ...

issues in oncology
issues in oncology

Socioeconomic Disparities in Mortality After Cancer Surgery Reflect Higher Failure-to-Rescue Rates in Hospitals Treating More Low-Income Patients

Although it has been found that lower socioeconomic status is associated with higher operative mortality, the factors explaining this disparity have not been clearly defined. In a study of major cancer surgery reported in JAMA Surgery, Reames et al found that hospitals with the highest proportion...

prostate cancer

Preclinical Study Suggests Benefits of Increased Tumor Perfusion and Reduced Tumor Hypoxia With Exercise in Prostate Cancer

In a study reported in the Journal of the National Cancer Institute, McCullough et al used an orthotopic rat model of prostate cancer to assess the effects of exercise on tumor hemodynamics and tissue hypoxia. Their findings of enhanced tumor perfusion and diminished tumor hypoxia suggest that...

Analysis of SWOG Trials Indicates No Survival Difference After 1 Year in Cancer Patients Treated In vs Out of Clinical Trials

In a study reported in the Journal of the National Cancer Institute, Unger et al evaluated whether cancer patients from SWOG clinical trials were similar to nontrial patients in baseline characteristics and survival. They found that, overall, trial participation in standard treatment arms did not...

breast cancer

Regular Physical Activity Reduces Breast Cancer Risk Irrespective of Age or Weight

Participating in athletic activities for more than an hour a day reduces the risk of breast cancer, and this applies to women of any age and any weight, regardless of geographic location, according to research presented at the 9th European Breast Cancer Conference in Glasgow. Compared with the...

breast cancer
issues in oncology

Genetic Testing May Improve Selection of Women With Estrogen Receptor–Positive Breast Cancer for 10 vs 5 Years of Hormonal Therapy

Genetic analyses of results from 1,125 postmenopausal women being treated for estrogen-responsive breast cancer have shown that some of them are more likely than others to have a late recurrence of their cancer and might benefit from 10 years of hormone therapy rather than 5 years. Women who had...

breast cancer

Postmastectomy Radiotherapy Benefits Women With Breast Cancer That Has Spread to One to Three Lymph Nodes

Women whose breast cancer has spread to just a few lymph nodes under their arm are less likely to have their disease recur or to die from it if they have radiotherapy after mastectomy, according to new research presented today at the European Breast Cancer Conference in Glasgow and published in The ...

prostate cancer
issues in oncology

Swedish Study Shows Lower Prostate Cancer Mortality in High-Incidence Areas

In a study reported in the Journal of the National Cancer Institute, Stattin et al found that rates of prostate cancer mortality, excess mortality in men with prostate cancer, and metastatic prostate cancer were lower in counties in Sweden with higher vs lower incidence of prostate cancer that...

skin cancer
head and neck cancer

Cutaneous Melanoma and Papillary Thyroid Carcinoma: Mutual Increased Risk

In a study reported in JAMA Otolaryngology-Head & Neck Surgery, Oakley et al found that papillary thyroid cancer increases the risk of cutaneous malignant melanoma and vice versa. In addition, the investigators found that patients with both cancers have a high frequency of BRAF V600E mutation. ...

issues in oncology
breast cancer

High Circulating Tumor Cell Count at Baseline and Increases in Count During Treatment Linked to Reduced Survival in Metastatic Breast Cancer

In a pooled analysis of individual patient data reported in The Lancet Oncology, Bidard et al found that baseline circulating tumor cell counts and increases in counts during treatment were highly prognostic in patients with metastatic breast cancer beginning new treatment and that addition of...

survivorship

Health Gap Between Adult Survivors of Childhood Cancer and Siblings Widens With Age

Adult survivors of childhood cancer face significant health problems as they age and are five times more likely than their siblings to develop new cancers, heart disease, and other serious health conditions beyond the age of 35, according to the latest findings from the Childhood Cancer Survivor...

issues in oncology
breast cancer

Shortening of Leukocyte Telomeres Associated With Increased All-Cause and Breast Cancer–Specific Mortality in Breast Cancer Patients

Short telomeres are associated with increased risk of cancer, but data on telomere length and mortality in breast cancer survivors are inconsistent. In a study reported in the Journal of the National Cancer Institute, Duggan et al found that decreases in telomere length between baseline and 30...

breast cancer

No Difference in Bone Mineral Density Changes With Adjuvant Exemestane vs Anastrozole in Women With Early Breast Cancer

In a companion study (MA.27B) to the open-label phase III National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) MA.27 trial in women with early breast cancer reported in The Lancet Oncology, Goss et al found that adjuvant aromatase inhibitor treatment with exemestane, a mildly...

American Association for Cancer Research Elects José Baselga, MD, PhD, as President-Elect 2014-2015

The members of the American Association for Cancer Research (AACR) have elected José Baselga, MD, PhD, Physician-in-Chief at Memorial Sloan Kettering Cancer Center in New York, as their President-Elect for 2014–2015. Dr. Baselga is an internationally recognized physician-scientist...

ASCO Urges Raising the Bar for Cancer Clinical Trials

The American Society of Clinical Oncology is calling on cancer researchers, clinical trial sponsors, and drug developers to employ clinical trial designs that aim to significantly extend the lives of people with cancer. In a Special Article published in the Journal of Clinical Oncology, Ellis...

prostate cancer

No Mortality Benefit From Primary Androgen-Deprivation Therapy for Most Men With Early-Stage Prostate Cancer

A large retrospective cohort study by Potosky et al of 15,170 men with early-stage prostate cancer has found that patients who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received no curative-intent treatment. Men...

supportive care
survivorship

NCCN Cancer Survivorship Guidelines Expanded to Address Two Common Conditions

The National Comprehensive Cancer Network (NCCN) has expanded its Survivorship Guidelines to include a section on cancer-associated cognitive impairment, and to include chemotherapy-induced peripheral neuropathy as a component of the Adult Cancer Pain section. The inaugural guidelines for...

colorectal cancer
issues in oncology

Report Shows More Screening Has Led to a 30% Drop in Colon Cancer Rates

Findings from a report by Siegel et al of the American Cancer Society (ACS) show that the rate at which people are diagnosed with colorectal cancer in the United States has dropped by 30% in the last 10 years among people aged 50 years and older. The researchers say the decline in incidence is due...

issues in oncology
prostate cancer

Circulating Tumor Cell Count and Early Change in Count Are Prognostic for Survival in First-Line Docetaxel Treatment of Prostate Cancer

As reported in the Journal of Clinical Oncology, Goldkorn et al assessed the prognostic value of circulating tumor cell counts in patients with metastatic castration-resistant prostate cancer receiving standard first-line docetaxel plus prednisone with or without atrasentan in the SWOG S0421 trial. ...

sarcoma

No Overall Survival Benefit of First-Line Doxorubicin Plus Ifosfamide vs Doxorubicin Alone in Advanced Soft-Tissue Sarcoma

In the open-label, phase III EORTC 62012 trial reported in The Lancet Oncology, Judson et al found that doxorubicin plus ifosfamide was not associated with any overall survival advantage compared with doxorubicin alone in patients with advanced or metastatic soft-tissue sarcoma. Progression-free...

Advertisement

Advertisement




Advertisement